MedCity News January 31, 2023
Paradigm, a new startup co-incubated by ARCH Venture Partners and General Catalyst, recently launched with $203 million in Series A funding. The company is focused on improving equitable access to trials by creating a less fragmented and more efficient clinical research ecosystem.
A new startup co-incubated by ARCH Venture Partners and General Catalyst launched last week with $203 million in Series A funding.
The New York-based company, called Paradigm, is focused on improving patients’ access to clinical research. Its financing was led by ARCH and General Catalyst, with participation from F-Prime Capital, GV, LUX Capital, Mubadala Capital, Magnetic Ventures and the American Cancer Society’s BrightEdge.
“Our team has been convinced of the need for a paradigm shift in clinical research...
Today's Sponsors
Today's Sponsor